Literature DB >> 19787556

Improving antithrombotic management in patients with atrial fibrillation: current status and perspectives.

Marcel Levi1, F D Richard Hobbs, Alan K Jacobson, Ron Pisters, Domenico Prisco, Artur Bernardo, Markus Haas, Jens Heidrich, Matt Rosenberg, Jørn Dalsgaard Nielsen, Walter A Wuillemin.   

Abstract

Despite overwhelming evidence of the benefits of risk-adjusted oral anticoagulation on stroke reduction in patients with atrial fibrillation (AF), there is still considerable undertreatment. A multidisciplinary expert group was formed to discuss issues surrounding anticoagulant treatment of patients with AF to try and achieve consensus on various aspects of the implementation of guidelines on oral anticoagulation therapy in AF. Panel members were cardiologists, hematologists, and laboratory and primary care physicians with specific expertise from Europe and the United States. One of the most important conclusions of the meeting was to enhance guideline adherence by better communication of the data showing that the benefits of stroke reduction outweigh the risk of bleeding associated with treatment with vitamin K antagonists. Management of oral anticoagulation therapy by dedicated centers, such as anticoagulation clinics, or by patient self-management may improve the quality of anticoagulation and facilitate the management of these patients and thereby further facilitate optimal antithrombotic management in patients with AF. Thieme Medical Publishers.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19787556     DOI: 10.1055/s-0029-1240013

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  8 in total

Review 1.  Review of race/ethnicity in non vitamin K antagonist oral anticoagulants clinical trials.

Authors:  Larry R Jackson; Eric D Peterson; Eze Okeagu; Kevin Thomas
Journal:  J Thromb Thrombolysis       Date:  2015-02       Impact factor: 2.300

2.  GP incentives to design hypertension and atrial fibrillation local quality-improvement schemes: a controlled before-after study in UK primary care.

Authors:  Timothy Smith; Christopher Fell; Harmony Otete; Umesh Chauhan
Journal:  Br J Gen Pract       Date:  2019-09-26       Impact factor: 5.386

Review 3.  Modern role for clopidogrel in management of atrial fibrillation and stroke reduction.

Authors:  Lars Maegdefessel; Junya Azuma; Philip S Tsao
Journal:  Vasc Health Risk Manag       Date:  2010-03-03

Review 4.  New options with dabigatran etexilate in anticoagulant therapy.

Authors:  Lars Maegdefessel; Joshua M Spin; Junya Azuma; Philip S Tsao
Journal:  Vasc Health Risk Manag       Date:  2010-05-25

5.  Home management of INR in the public health system: feasibility of self-management of oral anticoagulation and long-term performance of individual POC devices in determining INR.

Authors:  Sabrina da Silva Saraiva; Fernanda Andrade Orsi; Marcos Pereira Santos; Tania Machado; Silmara Montalvão; Carolina Costa-Lima; Erich Vinícius de Paula; Marina Pereira Colella; Joyce Annichino-Bizzacchi
Journal:  J Thromb Thrombolysis       Date:  2016-07       Impact factor: 2.300

6.  Antithrombotic prophylaxis of atrial fibrillation in an Italian real-world setting: a retrospective study.

Authors:  Giuliano Ermini; Valentina Perrone; Chiara Veronesi; Luca Degli Esposti; Giuseppe Di Pasquale
Journal:  Vasc Health Risk Manag       Date:  2017-07-05

7.  Analysis of Factors That Interrupt With INR Control in the First Anticoagulation Clinic Monitoring Jordanian Patients.

Authors:  Nairooz H Al-Momany; Zeid M Makahleh; Nadia A Al-Omari; Hana A Al-Sarayreh; Rawan O Momani
Journal:  Clin Appl Thromb Hemost       Date:  2019 Jan-Dec       Impact factor: 2.389

8.  Cost-Utility and Budget Impact Analysis of Implementing Anticoagulation Clinics and Point-of-Care Monitoring Devices in Anticoagulated Patients in Argentina.

Authors:  Osvaldo Ulises Garay; Gonzalo Guiñazú; Yolanda Patricia Adamczuk; Cristina Duboscq
Journal:  Pharmacoecon Open       Date:  2022-07-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.